cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Mink Therapeutics Inc
1 own
2 watching
Current Price
$2.24
$0
(0%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
75.68M
52-Week High
52-Week High
4.32
52-Week Low
52-Week Low
1.09
Average Volume
Average Volume
0M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization75.68M
icon52-Week High4.32
icon52-Week Low1.09
iconAverage Volume0M
iconDividend Yield--
iconP/E Ratio--
What does the Mink Therapeutics Inc do?
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
Read More
How much money does Mink Therapeutics Inc make?
News & Events about Mink Therapeutics Inc.
Globe Newswire
2 months ago
NEW YORK, Nov. 17, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc.,a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated ...
Globe Newswire
3 months ago
Allogeneic off-the-shelf iNKT cell therapy, agenT-797, alone and in combination with pembro/nivo reports early clinical activity in solid tumors, with 27% and 66% of patients, respectively, had a reduction of target and non-target lesions or disease stabilizationFirst immune cell therapy (agenT-797...
Globe Newswire
3 months ago
Conference Call on Thursday, November 3rd, 2022, at 8:30 a.m. ETNEW YORK, Oct. 20, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT...
Globe Newswire
4 months ago
Experts in disease pathways discuss clinical data of allo-iNKTsR&D strategy driving pipeline momentum, productivity, and innovationInternal scalable manufacturing of fully allogeneic iNKT cells; expanded capacity to ~700,000 dosesR&D event: November 10th from 4:00-6:00 pm ET, Boston, MA, and webcast...
Frequently Asked Questions
Frequently Asked Questions
What is Mink Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Mink Therapeutics Inc shares?
plus_minus_icon
How can I buy Mink Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Mink Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Mink Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Mink Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Mink Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Mink Therapeutics Inc?
plus_minus_icon
What percentage is Mink Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Mink Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$2.24
$0
(0%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00